Biosimilar ustekinumab will provide a treatment of autoimmune and inflammatory diseases such as plaque psoriasis, Crohn's disease and ulcerative colitis.
The Association for Accessible Medicines’ latest report found that Medicare Part D plans are slow to add new generics to their formularies and often place them on nongeneric pricing tiers.